NCT01790607View on ClinicalTrials.gov

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2013

Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG

ONO-2745 /CNS 7056

Trial Locations (3)

32803

Orlando Clinical Site, Orlando

33034

South Miami Clinical Site, South Miami

92803

Anaheim Clinical Site, Anaheim

Sponsors

Lead Sponsor

Ono Pharma USA Inc
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Ono Pharma USA Inc

INDUSTRY